Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3029 Adrenocortical Carcinoma Metastasic in Adult on Complete Response with EDP-M and Local Therapy: A Single Case Report

Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,

Keywords: ACC, chemotherapy, mitotane, local therapy,

#2993 Proposal of New Imaging Criteria for Evaluating the Response of Liver Metastases to Systemic Treatments in Digestive Neuroendocrine Tumors (NET) as an Alternative to RECIST 1.1

Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,

Keywords: imaging criteria, response evaluation, CT scan,

#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Cameselle-Garcia S, Sardo E, Landolfi S, Merino-Casabiel X, Sánchez J,

Keywords: Neuroendocrine Neoplasms, Inflammatory Biomarkers, Gastroenteropancreatic,

#2895 Survival Related to Treatment of Patients with Metastatic Neuroendocrine Lung Tumors Treated in a Brazilian Center

Introduction: Well-differentiated Neuroendocrine Pulmonary Tumors (NETp) are morphologically classified as Typical (TC) and Atypical Carcinoid (AC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tanaka H

Authors: Tanaka H, Petrocchi Corassa M, Carioca Freitas H, José de Barros e Silva M, Riechelmann R,

Keywords: Atypical Carcinoid, Typical Carcinoid, Neuroendocrine Pulmonary Tumors,

#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)

Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Duan H

Authors: Duan H, Ninatti G, Girod B, Ferri V, Guja K,

Keywords: NET, PRRT, ORR, PFS,

Abstract Submissions in 2022

Abstract submissions for 2022 will open in September 2021!

 

The 19th Annual ENETS Conference in 2022 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Virtual Conference 2021 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.